Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 May 18

PMID 29770141

Citations 8

Authors

Pedro Santos E Sousa

Clare L Bennett

Ronjon Chakraverty

Affiliations

Soon will be listed here.

Abstract

The skin is the most common target organ affected by graft-versus-host disease (GVHD), with severity and response to therapy representing important predictors of patient survival. Although many of the initiating events in GVHD pathogenesis have been defined, less is known about why treatment resistance occurs or why there is often a permanent failure to restore tissue homeostasis. Emerging data suggest that the unique immune microenvironment in the skin is responsible for defining location- and context-specific mechanisms of injury that are distinct from those involved in other target organs. In this review, we address recent advances in our understanding of GVHD biology in the skin and outline the new research themes that will ultimately enable design of precision therapies.

Citing Articles

Understanding and treatment of cutaneous graft-versus-host-disease.

Hong J, Fraebel J, Yang Y, Tkacyk E, Kitko C, Kim T Bone Marrow Transplant. 2023; 58(12):1298-1313.

PMID: 37730800 PMC: 11759061. DOI: 10.1038/s41409-023-02109-x.

RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea.

Zouali H, Lemasson J, Calugareanu A, Battail C, Michonneau D, Le Buanec H Blood Adv. 2022; 6(9):2805-2811.

PMID: 35008096 PMC: 9092416. DOI: 10.1182/bloodadvances.2021004707.

Human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles for chronic cutaneous graft-versus-host disease: A case report.

Norooznezhad A, Yarani R, Payandeh M, Hoseinkhani Z, Kiani S, Taghizadeh E J Cell Mol Med. 2021; 26(2):588-592.

PMID: 34873830 PMC: 8743661. DOI: 10.1111/jcmm.17114.

Incidence, Histopathological Features and Differential Diagnosis of Cutaneous Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation.

Hacisalihoglu U, Sahin D Sisli Etfal Hastan Tıp Bul. 2021; 55(1):68-75.

PMID: 33935538 PMC: 8085451. DOI: 10.14744/SEMB.2019.86729.

Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease.

Strattan E, Hildebrandt G Int J Mol Sci. 2021; 22(5).

PMID: 33673565 PMC: 7956846. DOI: 10.3390/ijms22052385.

References

Cai Y, Fleming C, Yan J . New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012; 9(4):302-9. PMC: 4132586. DOI: 10.1038/cmi.2012.15. View

Penack O, Holler E, van den Brink M . Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010; 115(10):1865-72. DOI: 10.1182/blood-2009-09-242784. View

Bennett C, Fallah-Arani F, Conlan T, Trouillet C, Goold H, Chorro L . Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin. Blood. 2011; 117(26):7063-9. PMC: 3336775. DOI: 10.1182/blood-2011-01-329185. View

Aractingi S, Carosella E, Gluckman E . [Cutaneous manifestations of graft versus host reaction]. Ann Dermatol Venereol. 1998; 125(9):620-7. View

Greinix H, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K . Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008; 14(2):208-19. DOI: 10.1016/j.bbmt.2007.10.009. View

Iijima N, Mattei L, Iwasaki A . Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A. 2010; 108(1):284-9. PMC: 3017177. DOI: 10.1073/pnas.1005201108. View

Zaid M, Wu J, Wu C, Logan B, Yu J, Cutler C . Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2016; 129(2):162-170. PMC: 5234220. DOI: 10.1182/blood-2016-08-735324. View

Teshima T, Reddy P, Zeiser R . Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant. 2015; 22(1):11-6. DOI: 10.1016/j.bbmt.2015.10.001. View

Byrd A, Belkaid Y, Segre J . The human skin microbiome. Nat Rev Microbiol. 2018; 16(3):143-155. DOI: 10.1038/nrmicro.2017.157. View

10.

Li H, Kaplan D, Matte-Martone C, Tan H, Venkatesan S, Johnson K . Langerhans cells are not required for graft-versus-host disease. Blood. 2010; 117(2):697-707. PMC: 3031488. DOI: 10.1182/blood-2010-07-299073. View

11.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

12.

Collin M, Hart D, Jackson G, Cook G, Cavet J, Mackinnon S . The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med. 2006; 203(1):27-33. PMC: 2118090. DOI: 10.1084/jem.20051787. View

13.

Koyama M, Kuns R, Olver S, Raffelt N, Wilson Y, Don A . Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med. 2011; 18(1):135-42. DOI: 10.1038/nm.2597. View

14.

Snover D . Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. Hum Pathol. 1984; 15(3):202-5. DOI: 10.1016/s0046-8177(84)80180-x. View

15.

Du J, Paz K, Flynn R, Vulic A, Robinson T, Lineburg K . Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood. 2017; 129(18):2570-2580. PMC: 5418639. DOI: 10.1182/blood-2017-01-758854. View

16.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

17.

Naik S, Bouladoux N, Wilhelm C, Molloy M, Salcedo R, Kastenmuller W . Compartmentalized control of skin immunity by resident commensals. Science. 2012; 337(6098):1115-9. PMC: 3513834. DOI: 10.1126/science.1225152. View

18.

Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz M, Lira S . Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004; 10(5):510-7. PMC: 4727841. DOI: 10.1038/nm1038. View

19.

Hill G, Olver S, Kuns R, Varelias A, Raffelt N, Don A . Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010; 116(5):819-28. DOI: 10.1182/blood-2009-11-256495. View

20.

Reddy P, Ferrara J . Immunobiology of acute graft-versus-host disease. Blood Rev. 2003; 17(4):187-94. DOI: 10.1016/s0268-960x(03)00009-2. View